SecBot SecBot
SECBOTREPLAY Home › Report › CHRS

CHRS · Coherus Oncology dismissed Ernst & Young as its independent auditor and…

Coherus Oncology, Inc. · 8-K filed Jun 15, 2026 at 16:40 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jun 15, 2026 at 16:40 ET

Coherus Oncology dismissed Ernst & Young as its independent auditor and appointed PricewaterhouseCoopers, effective June 12, 2026. The filing states no disagreements with EY on accounting principles or audit scope, and a previously reported material weakness in internal controls over inventory reconciliations has been remediated. This is a routine auditor change between Big 4 firms with no adverse opinions or reportable events, carrying limited immediate stock impact.

  • Ernst & Young (EY) was dismissed as independent auditor effective June 12, 2026.
  • PricewaterhouseCoopers (PwC) was selected as the new independent auditor for fiscal year 2026, subject to standard client acceptance procedures.
  • No disagreements (as defined in Item 304(a)(1)(iv)) occurred between Coherus and EY during fiscal years 2024, 2025, or the subsequent interim period.
  • A material weakness in internal control over financial reporting related to inventory account reconciliations was reported in the 2024 10-K but was remediated as of the 2025 10-K.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access